Journal article · 2024 · Open access
24 CAR-T cell therapy for autoimmune diseases: lupus in focus
Lupus Science & Medicine, A14.2–A15 · Published 1 September 2024 · DOI 10.1136/lupus-2024-la.25
In brief
“24 CAR-T cell therapy for autoimmune diseases: lupus in focus” is a 2024 journal article by Ronald van Vollenhoven, published in Lupus Science & Medicine. OpenAlex counts 1 citations as of 19 November 2026. It is open access under a CC BY-NC licence: the full text is free to read at Lupus Science & Medicine.
- Citations
- 1
- Most cited in
- 2025 (1)
- References
- 17
- Authors
- 1
Abstract
Chimeric antigen receptor (CAR)-T cells are a novel high-tech treatment modality that over the past years has gained an important role in the treatment of hematological malignancies. The basic principle for currently available CAR-T cells is that the patient’s own T lymphocytes are harvested and engineered in vitro to express a receptor on their surface of the desired specificity; in most cases a receptor that binds the CD19 molecule that is present on B-lineage cells. These cells are then reintroduced into the patient where they expand and bring about a very profound depletion of the target cells. Because autoreactive B-cells play an important role in many autoimmune diseases it has been proposed that CAR-T cells could be utilized to treat such diseases as well.Clinical experiences have now been published including small numbers of patients with a variety of autoimmune diseases including systemic lupus erythematosus (SLE), and for the most part these reports have been encouraging: along with the depletion of B cells, autoantibody titres decreased, and rapid and complete clinical responses were seen in many patients.1 2 B-cell reconstitution took place as expected, and vaccine responses were restored, but autoantibodies did not re-emerge, and clinical relapses did not occur in the lupus patients reported to date; in some patients a treatment-free remission for over two years has now been documented and CAR-T cell therapy was well-tolerated in these patients.The main questions that now must be addressed are:Is the abolition of autoreactive B-cell activity permanent?If so, is it sufficient for patients with SLE to remain free of disease?If so, can the necessary degree of B-cell depletion be achieved by other means?What are the true risks and possible side effects of CAR-T cell therapy in patients with autoimmune diseases?What role does ‘conditioning chemotherapy’ have in CAR-T cell therapy?How should patients be selected for CAR-T cell therapy?References Mackensen A, Müller F, Mougiakakos D, et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat Med. 2022;28(10):2124–32. doi: 10.1038/s41591-022-02017-5.Muller F, Taubmann J, Bucci L, et al. CD19 CAR T-cell therapy in autoimmune disease - A case series with follow-up. N Engl J Med. 2024;390(8):687–700. doi: 10.1056/NEJMoa2308917.Learning Objectives At the end of this presentation participants will be able to:Discuss the published and reported experiences with CAR-T cells in the treatment of SLEExplain the basic principles of CAR-T cell therapy, the expected mechanistic effects in the patient, and the risks and potential side effects of the treatmentDiscuss the main outstanding questions currently before us regarding this therapyDiscuss the potential breakthroughs in the treatment of…
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
van Vollenhoven, R. (2024). 24 CAR-T cell therapy for autoimmune diseases: lupus in focus. Lupus Science & Medicine, A14.2–A15. https://doi.org/10.1136/lupus-2024-la.25
MLA 9
van Vollenhoven, Ronald. “24 CAR-T cell therapy for autoimmune diseases: lupus in focus.” Lupus Science & Medicine, 2024, pp. A14.2–A15. https://doi.org/10.1136/lupus-2024-la.25.
Chicago
van Vollenhoven, Ronald. 2024. “24 CAR-T cell therapy for autoimmune diseases: lupus in focus.” Lupus Science & Medicine: A14.2–A15. https://doi.org/10.1136/lupus-2024-la.25.
Harvard
van Vollenhoven, R. (2024) ‘24 CAR-T cell therapy for autoimmune diseases: lupus in focus’, Lupus Science & Medicine, pp. A14.2–A15. doi:10.1136/lupus-2024-la.25.
IEEE
R. van Vollenhoven, “24 CAR-T cell therapy for autoimmune diseases: lupus in focus,” Lupus Science & Medicine, pp. A14.2–A15, 2024, doi: 10.1136/lupus-2024-la.25.
BibTeX
@article{vanvollenhoven2024cell,
title = {{24 CAR-T cell therapy for autoimmune diseases: lupus in focus}},
author = {van Vollenhoven, Ronald},
journal = {Lupus Science \& Medicine},
year = {2024},
pages = {A14.2--A15},
doi = {10.1136/lupus-2024-la.25},
url = {https://doi.org/10.1136/lupus-2024-la.25}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- CAR T-cell therapy
- systemic lupus erythematosus
- autoimmune disease
- CD19 CAR T cells
- B-cell depletion
- autoreactive B cells
- autoantibodies
- B cell reconstitution
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
van Vollenhoven, R. (2024). 24 CAR-T cell therapy for autoimmune diseases: lupus in focus. Lupus Science & Medicine, A14.2–A15. https://doi.org/10.1136/lupus-2024-la.25
How many times has this paper been cited?
1 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Lupus Science & Medicine: sign in and open the PDF from this page.
Who wrote this paper?
Ronald van Vollenhoven.
What is the DOI of this paper?
10.1136/lupus-2024-la.25, permanently at https://doi.org/10.1136/lupus-2024-la.25. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.